Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15708179 | 1.00 | MAOA (0.36) | MAOATMEM97HRH3ARCA2 | |
| SCHEMBL15708057 | 0.93 | TMEM97 (0.38) | TMEM97ARCA2CA9 | |
| SCHEMBL15724836 | 0.93 | TMEM97 (0.38) | TMEM97ARCA2CA9 | |
| SCHEMBL15708047 | 0.91 | ENPP2 (0.36) | TMEM97HRH3ARF2TPSAB1 | |
| SCHEMBL15724838 | 0.91 | ENPP2 (0.36) | TMEM97HRH3ARF2TPSAB1 | |
| SCHEMBL15708119 | 0.91 | MAPK1 (0.38) | MAOATMEM97HRH3F2TPSAB1 | |
| SCHEMBL15727614 | 0.91 | MAPK1 (0.38) | MAOATMEM97HRH3F2TPSAB1 | |
| SCHEMBL15708134 | 0.91 | TMEM97 (0.35) | TMEM97HRH3F2TPSAB1TPSD1 | |
| SCHEMBL15707997 | 0.91 | TMEM97 (0.35) | TMEM97HRH3ARCA2CA9 | |
| SCHEMBL15724816 | 0.91 | TMEM97 (0.35) | TMEM97HRH3F2TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | MAOA 1280/4885TMEM97 3459/4885HRH3 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.